机构:[1]State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.[2]Beijing Bo'ai Hospital, China Rehabilitation Research Center, Beijing, China.[3]Longgang District People's Hospital of Shenzhen, Shenzhen, China.深圳市龙岗区人民医院深圳市人民医院深圳医学信息中心[4]Bioyong Technologics Inc., Beijing, China.[5]Department of Pediatrics, The First Affiliated Hospital, Guangxi Medical University, Nanning, China.[6]Beijing Hypertension League Institute, Beijing, China.[7]Department of Laboratory Medicine, Beijing Tongren Hospital, Capital Medical University, Beijing, China.医技科室检验科首都医科大学附属北京同仁医院首都医科大学附属同仁医院[8]Department of Nutrition and Health, China Agricultural University, Beijing, China.
Thalassaemia is one of the most common inherited monogenic diseases worldwide with a heavy global health burden. Considering its high prevalence in low and middle-income countries, a cheap, accurate and high-throughput screening test of thalassaemia prior to a more expensive confirmatory diagnostic test is urgently needed.In this study, we constructed a machine learning model based on MALDI-TOF mass spectrometry quantification of haemoglobin chains in blood, and for the first time, evaluated its diagnostic efficacy in 674 thalassaemia (including both asymptomatic carriers and symptomatic patients) and control samples collected in three hospitals. Parameters related to haemoglobin imbalance (α-globin, β-globin, γ-globin, α/β and α-β) were used for feature selection before classification model construction with 8 machine learning methods in cohort 1 and further model efficiency validation in cohort 2.The logistic regression model with 5 haemoglobin peak features achieved good classification performance in validation cohort 2 (AUC 0.99, 95% CI 0.98-1, sensitivity 98.7%, specificity 95.5%). Furthermore, the logistic regression model with 6 haemoglobin peak features was also constructed to specifically identify β-thalassaemia (AUC 0.94, 95% CI 0.91-0.97, sensitivity 96.5%, specificity 87.8% in validation cohort 2).For the first time, we constructed an inexpensive, accurate and high-throughput classification model based on MALDI-TOF mass spectrometry quantification of haemoglobin chains and demonstrated its great potential in rapid screening of thalassaemia in large populations.Key messagesThalassaemia is one of the most common inherited monogenic diseases worldwide with a heavy global health burden.We constructed a machine learning model based on MALDI-TOF mass spectrometry quantification of haemoglobin chains to screen for thalassaemia.
基金:
Shenzhen Science and technology
project (JCYJ20190814121801683) and National
Megaprojects for Key Infectious Diseases
(2018ZX10732202-003).
第一作者机构:[1]State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.
共同第一作者:
通讯作者:
通讯机构:[1]State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China.[8]Department of Nutrition and Health, China Agricultural University, Beijing, China.[*1]State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of Lifeomics, Beijing, China[*2]Department of Nutrition and Health, China Agricultural University, Beijing, China
推荐引用方式(GB/T 7714):
Zhang Jian,Liu Zhizhong,Chen Ribing,et al.A MALDI-TOF mass spectrometry-based haemoglobin chain quantification method for rapid screen of thalassaemia.[J].ANNALS OF MEDICINE.2022,54(1):293-301.doi:10.1080/07853890.2022.2028002.
APA:
Zhang Jian,Liu Zhizhong,Chen Ribing,Ma Qingwei,Lyu Qian...&Sun Wei.(2022).A MALDI-TOF mass spectrometry-based haemoglobin chain quantification method for rapid screen of thalassaemia..ANNALS OF MEDICINE,54,(1)
MLA:
Zhang Jian,et al."A MALDI-TOF mass spectrometry-based haemoglobin chain quantification method for rapid screen of thalassaemia.".ANNALS OF MEDICINE 54..1(2022):293-301